Trial Profile
A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Malignant melanoma
- Focus Therapeutic Use
- 14 Jan 2021 Primary endpoint of progress-free survival has been met, according to results published in the Journal of Clinical Oncology.
- 14 Jan 2021 Status changed from recruiting to completed, according to results published in the Journal of Clinical Oncology.
- 14 Jan 2021 Results published in the Journal of Clinical Oncology